Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onvansertib - Cardiff Oncology

Next Previous
Drug Profile

Onvansertib - Cardiff Oncology

Alternative Names: NMS-1286937; NMS-P937; Onvansertib-fumarate; PCM-075; PCM-075H

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Cardiff Oncology
  • Class Antineoplastics; Piperazines; Pyrazoles; Quinazolines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Colorectal cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer
  • Phase I/II Triple negative breast cancer
  • Phase I Chronic myelomonocytic leukaemia
  • Preclinical Medulloblastoma; Ovarian cancer
  • No development reported Lung cancer; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 08 Apr 2024 Efficacy data from a phase Ib/II ONSEMBLE trial in Colorectal cancer released by Cardiff Oncology
  • 08 Apr 2024 Pharmacodynamics data from preclinical studies in Ovarian cancer, Colorectal cancer and Small cell lung cancer were released by Cardiff Oncology
  • 29 Feb 2024 Cardiff Oncology terminates a phase II CRDF-003 trial in Colorectal cancer (In the elderly, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, In adults, Adjunctive treatment) in USA (PO) to focus on its new lead program in first-line RAS-mutated mCRC (NCT05593328)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top